For a comprehensive listing of Dr. Lesinski's publications, visit PubMed or ResearchGate.

Selected Publications include:

Bill M.A., Bakan C., Benson Jr., D.M., Fuchs J., Young G., Lesinski G.B. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Molecular Cancer Therapeutics 8:2726-2735, 2009.

Bill, M.A., Fuchs, J.R., Li, C., Yui, J., Bakan, C., Benson Jr., D.M., Schwartz, E.B., Abdelhamid, D., Lin, J., Hoyt, D.G., Fossey, S.L., Young, G.S., Carson, W.E. 3rd, Li, P-K, Lesinski, G.B. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Molecular Cancer. 9:165, 2010.

Mundy, B.L., Young, G.S., Bauer, T., Binkley, E., Bloomston, M., Bill, M.A., Bekaii-Saab, T., Carson, W.E. 3rd, Lesinski, G.B. Distinct Myeloid-Derived Suppressor Cell Subsets Correlate with Plasma Interleukin-6 and Interleukin-10 and Reduce Interferon-alpha Signal Transduction in CD4+ T cells from Patients with Gastrointestinal Malignancy. Cancer Immunology, Immunotherapy. Sept;60(9):1269-79, 2011.

Sullivan, N.J., Tober, K.L., Burns, E., Schick, J.S., Riggenbach, J.A., Mace, T., Bill, M.A., Young, G.S., Oberyszyn, T.M., Lesinski, G.B. Catalase Promotes a Sex Discrepancy in Myeloid-Derived Suppressor Cell Expansion in a Mouse Model of Ultraviolet Light-Induced Skin Cancer. Journal of Investigative Dermatology. Mar;132(3 Pt 1):695-702, 2012.

Bill, M.A., Nicholas, C., Mace, T., Etter, J.P., Li, C., Schwartz, E.B., Fuchs, J.R., Young, G.S., Lin, L., Lin, J., He, L., Phelps, M., Li, P-K., Lesinski, G.B. Structurally Modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. Plos One. 7(8):e40724, 2012.

Mace, T.A., Ameen, Z., Frankel, W., Collins, A., Wojcik, S., Mair, M., Young, G.S., Fuchs, J.R., Eubank, T., Bekaii-Saab, T., Bloomston, M., Lesinski, G.B. Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Research. May 15;73(10):3007-3018, 2013.

Yang, J., Bill, M.A., Young, G.S., La Perle, K., Landesman, Y., Shacham, S., Kauffman, M., Senapedis, W., Kashyap, T., Saint-Martin, J-R., Kendra, K., Lesinski, G.B. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. Plos One, Jul 24;9(7):e102983, 2014.

Aguilar, L.K., Shirley, L.A., Chung, V.M., Marsh, C.L., Walker, J., Coyle, W., Marx, H., Bekaii-Saab, T., Lesinski, G.B., Swanson, B., Sanchez, D., Manzanera, A.G., Aguilar-Cordova, E., Bloomston, M. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunology Immunotherapy, 64(6):727-736, 2015.

Lesinski, G.B., Reville, P.K., Mace, T.A., Young, G.S., Ahn-Jarvis, J., Thomas-Ahner, J., Vodovotz, Y., Ameen, Z., Grainger, E., Riedl, K., Schwartz, S., Clinton, S.K. Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced pro-inflammatory cytokines and immune suppressive cells. Cancer Prevention Research, Nov;8(11):1036-1044, 2015.

Ahn-Jarvis, J.H., Clinton, S.K., Grainger, E.M., Riedl, K.M., Schwartz, S.J., Lee, M-L.T., Cruz-Cano, R., Young, G.S., Lesinski, G.B., Vodovotz, Y. Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer. Cancer Prevention Research, Nov;8(11):1045-1054, 2015.

Mace, T.A., Shakya, R., Elnaggar, O., Wilson, K., Komar, H.M., Yang, J., Pitarresi, J.R., Young, G.S., Ostrowski, M.C., Ludwig, T., Bekaii-Saab, T., Bloomston, M., Lesinski, G.B. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget. Dec 29;6(42):44509-44522, 2015.

Ahn, D.H., Gulcin, H., Hancioglu, B., Lesinski, G.B., Timmers, C.D., Bekaii-Saab, T. Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. Oncotarget. Feb 2;7(5):5306-5312, 2016.

Farren, M.R., Mace, T., Geyer, S., Mikhail, S., Wu, C., Ciombor, K.K., Tahiri, S., Ahn, D., Noonan, A.M., Villalona-Calero, M.A., Bekaii-Saab, T., Lesinski, G.B. Systemic immune activity predicts overall survival in treatment naïve patients with metastatic pancreatic cancer. Clinical Cancer Research, May 15;22(10):2565-2574, 2016.

Noonan, A.M., Farren, M.R., Geyer, S.M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K.K., Pant, S., Aparo, S., Sexton, J., Marshall, J.L., Mace, T.A., Wu, C.S., El-Rayes, B., Timmers, C.D., Zwiebel, J., Lesinski, G.B., Villalona-Calero, M.A., Bekaii-Saab. T.S. Randomized Phase II Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, Jun;24(6):1150-1158, 2016.

Mace, T.A., Shakya, R., Pitarresi, J.R., Swanson, B., McQuinn, C.W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., Zhong, X., Zimmers, T.A., Ostrowski, M.C., Ludwig, T., Bloomston, M., Bekaii-Saab, T., Lesinski, G.B. IL-6 and PD-L1 antibody blockade combination therapy reduces tumor progression in murine models of pancreatic cancer. Gut. Oct 21, 2016. [e-pub ahead of print].

Talbert, E.E., Yang, J., Mace, T., Farren, M.R., Farris, A.B., Young, G.S., Elnaggar, O., Che, Z., Timmers, C., Rajasekera, P., Maskarinec, J.M., Bloomston, M., Bekaii-Saab, T., Guttridge, D.C., Lesinski, G.B. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities. Molecular Cancer Therapeutics, Nov 3, 2016. [e-pub ahead of print].